Format
Sort by
Items per page

Send to

Choose Destination

Best matches for selegiline:

The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). Miklya I et al. Mol Psychiatry. (2016)

Critical appraisal of selegiline transdermal system for major depressive disorder. Cristancho MA et al. Expert Opin Drug Deliv. (2016)

Metabolism of selegiline [(-)-deprenyl)]. Kalász H et al. Curr Med Chem. (2014)

Search results

Items: 1 to 20 of 2869

1.

Geroprotection in the future. In memoriam of Joseph Knoll: The selegiline story continues.

Ferdinandy P, Yoneda F, Muraoka S, Fürst S, Gyires K, Miklya I.

Eur J Pharmacol. 2019 Nov 16:172793. doi: 10.1016/j.ejphar.2019.172793. [Epub ahead of print]

PMID:
31743738
2.

Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series.

Lu BY, Agapoff JR, Olson DJ, Williams SR, Roller A, Goebert D.

J Affect Disord. 2019 Oct 31;262:40-42. doi: 10.1016/j.jad.2019.10.050. [Epub ahead of print]

PMID:
31706158
3.

Pramipexole and Selegiline Combination Therapy in a Case of Treatment-Resistant Depression.

Moirand R, Galvao F, Dondé C.

J Clin Psychopharmacol. 2019 Nov/Dec;39(6):684-685. doi: 10.1097/JCP.0000000000001139. No abstract available.

PMID:
31688405
4.

[The effect of a neuroprotective dose of isatin or deprenyl to mice on the profile of brain isatin-binding proteins].

Buneeva OA, Kapitsa IG, Ivanova EA, Kopylov AT, Zgoda VG, Medvedev AE.

Biomed Khim. 2019 Aug;65(5):407-417. doi: 10.18097/PBMC20196505407. Russian.

PMID:
31666414
5.

Selegiline.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2017 Jul 21.

6.

Parkinson Disease Agents.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.
2017 Jul 20.

7.

Synthetic enhancer compounds, besides acting on biogenic amine system, influence the glutamate transmission and stress response.

Knoll J, Zelena D, Timar J, Baghy K, Mervai Z, Miklya I.

Behav Brain Res. 2019 Oct 11:112290. doi: 10.1016/j.bbr.2019.112290. [Epub ahead of print]

PMID:
31610214
8.

Comparison of the proteome patterns of adipose-derived stem cells with those treated with selegiline using a two dimensional gel electrophoresis analysis.

Mardani M, Tiraihi T, Bathaie SZ, Mirnajafi-Zadeh J.

Biotech Histochem. 2019 Oct 7:1-10. doi: 10.1080/10520295.2019.1656345. [Epub ahead of print]

PMID:
31589072
9.

Selegiline: a molecule with innovative potential.

Tábi T, Vécsei L, Youdim MB, Riederer P, Szökő É.

J Neural Transm (Vienna). 2019 Sep 27. doi: 10.1007/s00702-019-02082-0. [Epub ahead of print] Review.

PMID:
31562557
10.

Selegiline Recovers Synaptic Plasticity in the Medial Prefrontal Cortex and Improves Corresponding Depression-Like Behavior in a Mouse Model of Parkinson's Disease.

Okano M, Takahata K, Sugimoto J, Muraoka S.

Front Behav Neurosci. 2019 Aug 2;13:176. doi: 10.3389/fnbeh.2019.00176. eCollection 2019.

11.

Possible involvement of PI3K/AKT/mTOR signaling pathway in the protective effect of selegiline (deprenyl) against memory impairment following ischemia reperfusion in rat.

Amini-Khoei H, Saghaei E, Mobini GR, Sabzevary-Ghahfarokhi M, Ahmadi R, Bagheri N, Mokhtari T.

Neuropeptides. 2019 Oct;77:101942. doi: 10.1016/j.npep.2019.101942. Epub 2019 Jun 28.

PMID:
31272684
12.

Computational Insight into the Mechanism of the Irreversible Inhibition of Monoamine Oxidase Enzymes by the Antiparkinsonian Propargylamine Inhibitors Rasagiline and Selegiline.

Tandarić T, Vianello R.

ACS Chem Neurosci. 2019 Aug 21;10(8):3532-3542. doi: 10.1021/acschemneuro.9b00147. Epub 2019 Jul 2.

PMID:
31264403
13.

The emergence of new antidepressants for clinical use: Agomelatine paradox versus other novel agents.

Fasipe OJ.

IBRO Rep. 2019 Jan 9;6:95-110. doi: 10.1016/j.ibror.2019.01.001. eCollection 2019 Jun. Review.

14.

Monoamine Oxidases (MAOs) as Privileged Molecular Targets in Neuroscience: Research Literature Analysis.

Yeung AWK, Georgieva MG, Atanasov AG, Tzvetkov NT.

Front Mol Neurosci. 2019 May 29;12:143. doi: 10.3389/fnmol.2019.00143. eCollection 2019.

15.

Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson's disease: a meta-analysis.

Jiang DQ, Li MX, Jiang LL, Chen XB, Zhou XW.

Aging Clin Exp Res. 2019 Jun 7. doi: 10.1007/s40520-019-01232-4. [Epub ahead of print] Review.

PMID:
31175606
16.

Influence of DRD1 and DRD3 Polymorphisms in the Occurrence of Motor Effects in Patients with Sporadic Parkinson's Disease.

Dos Santos EUD, Duarte EBC, Miranda LMR, Asano AGC, Asano NMJ, Maia MMD, de Souza PRE.

Neuromolecular Med. 2019 Sep;21(3):295-302. doi: 10.1007/s12017-019-08549-3. Epub 2019 May 22.

PMID:
31119645
17.

Design of selegiline-loaded bio-nanosuspension for the management of depression using novel bio-retardant from Manilkara zapota.

Tyagi Y, Madhav NVS.

Drug Dev Ind Pharm. 2019 Aug;45(8):1351-1360. doi: 10.1080/03639045.2019.1619760. Epub 2019 May 28.

PMID:
31084445
18.
19.

Long-Term Selegiline Monotherapy for the Treatment of Early Parkinson Disease.

Mizuno Y, Hattori N, Kondo T, Nomoto M, Origasa H, Takahashi R, Yamamoto M, Yanagisawa N.

Clin Neuropharmacol. 2019 Jul/Aug;42(4):123-130. doi: 10.1097/WNF.0000000000000343.

PMID:
31045589
20.

Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson's disease: current status.

Müller T, Möhr JD.

Expert Opin Drug Metab Toxicol. 2019 May;15(5):429-435. doi: 10.1080/17425255.2019.1607292. Epub 2019 Apr 24. Review.

PMID:
31017021

Supplemental Content

Loading ...
Support Center